Symbol="ARGX"
AssetType="Common Stock"
Name="argenx NV ADR"
Description="argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands."
CIK="1697862"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="INDUSTRIEPARK ZQIJNAARDE 7, BUILDING C B-9052, ZWIJNAARDE, BE"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="29513296000"
EBITDA="-479285760"
PERatio="None"
PEGRatio="0"
BookValue="2.032"
DividendPerShare="0"
DividendYield="0"
EPS="-9.31"
RevenuePerShareTTM="0.324"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.151"
ReturnOnEquityTTM="-0.265"
RevenueTTM="639411000"
GrossProfitTTM="-251786000"
DilutedEPSTTM="-9.31"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="6.3"
AnalystTargetPrice="570.14"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="78.22"
PriceToBookRatio="7.24"
EVToRevenue="72.3"
EVToEBITDA="-21.25"
Beta="0.429"
num_52WeekHigh="550.76"
num_52WeekLow="333.07"
num_50DayMovingAverage="422.79"
num_200DayMovingAverage="388.34"
SharesOutstanding="58537000"
DividendDate="None"
ExDividendDate="None"
symbol="ARGX"
open="501.48"
high="504.06"
low="494.29"
price="500.17"
volume="196973.00"
latest_trading_day="2023-08-02"
previous_close="504.04"
change="-3.87"
change_percent="-0.7678%"
aroon_positive_momentum_days="69"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="High Volatility / Hold Signal"
volume_analysis="Trending Low"
value_analysis="Bearish Trend"
Aroon_change="FALSE"
Aroon_momentum="69"
Volume_recent_avg="276541"
Change_recent_avg="0.61"
Delta_recent_avg="8.88"
Variance_recent_avg="4.44"
Change_ratio_recent_avg="0.14"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="69"
Aroon_momentum_negative="31"
image_negative_thumbnail_id_1="150"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0026.jpeg"
image_negative_thumbnail_id_2="123"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0053.jpeg"
image_neutral_thumbnail_id_1="545"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0054.jpeg"
image_neutral_thumbnail_id_2="591"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0008.jpeg"
image_positive_thumbnail_id_1="1014"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0176.jpeg"
image_positive_thumbnail_id_2="606"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0102.jpeg"
image_professor_thumbnail_id_1="1169"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
image_professor_thumbnail_id_2="1176"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0010.jpeg"
